BioReliance Corporation Chief Scientific Advisor Wins Prestigious Awards
ROCKVILLE, MD – November 30, 2012 -- Dr. Marilyn Aardema, Chief Scientific Advisor for Toxicology at BioReliance was recently named the recipient of awards for her outstanding achievements during her distinguished career. The two awards from the Environmental Mutagen Society (EMS) and the Genetic Toxicology Association (GTA), represent highest honors conferred by these societies.
BioReliance Corporation is a leading contract services company in the area of product safety. Its clients include pharmaceutical, biotechnology, chemical, consumer product, medical device and academic organizations.
In September, Dr. Aardema was named the recipient of the 2012 Alexander Hollaender Award by the Environmental Mutagen Society (EMS). The Alexander Hollaender Award is conferred in recognition of long‐standing service in the application of the principles and techniques of environmental mutagenesis to protect human health and is the highest honor bestowed by EMS. In October, Dr. Aardema won the highest award from the paramount society for Genetic Toxicology, the Genetic Toxicology Association (GTA), when she was named the Excellence in Science Award winner for 2012, conferred to a member of the GTA in recognition of outstanding contributions in the applications of Genetic Toxicology and for having provided exemplary representation of the three pillars of GTA: Industry, Regulatory and Basic research.
Dr. Aardema received her PhD in Genetics from The University of Tennessee‐Oak Ridge Graduate School of Biomedical Sciences, and went on to establish herself as an internationally recognized expert and highly influential leader in applied genetic toxicology. In over 30 years of devoted service to her field, Dr. Aardema has over 75 publications, has lead international consortia and contributed to numerous societies, working groups and scientific panels. Most recently as the Chief Scientific Advisor for Toxicology at BioReliance, Dr. Aardema has provided important impact and innovation through the pioneering development of 3D skin culture models and alternative in vitro testing strategies in genetic toxicology.
BioReliance was acquired by Sigma-Aldrich Corporation, in January, 2012 to supply customers access to a powerful, single-point provider whose products and services span the drug discovery, development and commercialization pipeline. As part of the SAFC business unit, BioReliance is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health services. BioReliance has over 700 employees and has laboratory operations in Rockville, MD and Scotland. For more information, visit www.bioreliance.com.
SAFC, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life science and high technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline utilizing its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.safcglobal.com.
# # #
Copyright © 2017 Sigma-Aldrich Co. LLC. All Rights Reserved. Reproduction of any materials from the site is strictly forbidden without permission. Sigma-Aldrich brand products are sold exclusively through Sigma-Aldrich Co. LLC. Sigma-Aldrich Corp. is a subsidiary of Merck KGaA, Darmstadt, Germany Terms | Privacy